Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)Quviviq Approved for the Treatment of Insomnia

Orexin receptor antagonists work by suppressing the wake drive through blocking wake-promoting neuropeptides. Daridorexant is the third dual-orexin inhibitor to receive FDA approval for people with difficulty in sleep onset or sleep maintenance.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form